Home › Head and Neck Squamous Cell Carcinoma › Illinois
Head and Neck Squamous Cell Carcinoma clinical trials in Illinois
33 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in Illinois.
Cities in Illinois
- Chicago29 studies
- Evanston7 studies
- Springfield6 studies
- Champaign6 studies
- Charleston6 studies
- Naperville6 studies
- Cicero6 studies
- Decatur6 studies
- Danville6 studies
- Waukegan5 studies
- Aurora5 studies
- Joliet5 studies
- Peoria5 studies
- Bloomington5 studies
- North Peoria4 studies
- Galesburg4 studies
- Elgin3 studies
- Arlington Heights3 studies
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- and 14 more
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Nov 12, 2026 · NCT04671667BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- Illinois CancerCare-Carthage, Carthage
- and 36 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT05136196Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Advocate Good Shepherd Hospital, Barrington
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
- and 27 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT06589804Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
- University of Illinois Cancer Center, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT04198766A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06465069High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- Illinois CancerCare-Bloomington, Bloomington
- and 40 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06992427A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- The University of Chicago Medical Center (UCMC), Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT06385080A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- The University of Chicago Medical Center (UCMC), Chicago
- Cancer Care Specialists of Central Illinois, O'Fallon
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07276399FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT06788990A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT07109726Ordastobart (INBRX-106) Add-on to Pembrolizumab in 1L HPV+ PD-L1+ R/M OPSCC (HexAgon-HN)
- University of Illinois Cancer Center, Chicago
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06295731A Study to Investigate ALE.P02 as a Monotherapy or in Combination With Pembrolizumab in Adult Patients With Selected CLDN1+ Solid Tumors
- The University of Chicago Medical Center - Oncology, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 28, 2026 · NCT06747585A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 26, 2026 · NCT06330064A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Northwestern University, Evanston
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 22, 2026 · NCT06769698SMP-3124LP in Adults With Advanced Solid Tumors
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06526819Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 257378, Chicago
- University of Chicago Medical Center /ID# 258197, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 14, 2026 · NCT06084481A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma
- University of Chicago, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 8, 2026 · NCT07768189Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT05176483Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Good Shepherd Hospital, Barrington
- and 53 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Northwestern University Feinberg School of Medicine, Chicago
- Cancer Care Specialists of Illinois, Decatur
- Illinois Cancer Care, Peoria
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT06163534A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- University of Chicago Medical Center /ID# 276638, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07241039Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- and 21 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Ingalls Family Care Center, Calumet City
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- and 13 more
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jul 6, 2026 · NCT04389632Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT05005403A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 2
Ages 18 and older · All sexes · Updated May 12, 2026 · NCT05420948A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
- The University of Chicago, Chicago
RecruitingPhase 2/3
Ages 18 to 100 · All sexes · Updated Apr 23, 2026 · NCT05893888A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Illinois Cancer Center, Chicago
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- The University of Chicago, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Mar 4, 2026 · NCT05526924A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- The University of Chicago Comprehensive Cancer Center, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Feb 13, 2026 · NCT06778863A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 4, 2025 · NCT05902988A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2025 · NCT05107674From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.